Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations

Clin Lung Cancer. 2015 Sep;16(5):e97-9. doi: 10.1016/j.cllc.2015.02.005. Epub 2015 Mar 5.

Authors

Emily H Castellanos¹, Gabriel Rivera², Heather Wakelee², Leora Horn³

Affiliations

¹ Vanderbilt University Medical Center, Nashville, TN. Electronic address: Emily.hon@vanderbilt.edu.
² Stanford University Medical Center, Stanford, CA.
³ Vanderbilt University Medical Center, Nashville, TN.

PMID: 25842367
DOI: 10.1016/j.cllc.2015.02.005

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Afatinib
Aged
Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Drug Resistance, Neoplasm
ErbB Receptors / genetics*
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Middle Aged
Mutation
Panitumumab
Quinazolines / administration & dosage

Substances

Antibodies, Monoclonal
Quinazolines
Afatinib
Panitumumab
EGFR protein, human
ErbB Receptors